drugset
drugset / Trial / NCT06094712

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

NCT06094712 ↗

Phase 1 Completed 8 enrolled Corcept Therapeutics
NaSingle-groupOpen-labelOther

Summary

A study designed to characterize the pharmacokinetic (PK) profile of CORT125134 following a single 150-mg oral dose of the Phase 2 capsule formulation of CORT125134 in 8 healthy male subjects.

Timeline

Start
2016-04-07
Primary completion
2016-04-27
Completion
2016-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Relacorilant Small molecule 150 mg Oral

Indications

No indication recorded.